Full-Time
Staff Software Engineer
Posted on 10/31/2025
Asimov
51-200 employees
Genetic design software with engineered cells
Compensation Overview
$180k - $215k/yr
Boston, MA, USA
In Person
 Software Engineering (1) |
|---|
- 10+ years of experience in software development
- technical expertise in Python 3, Strawberry, SQLAlchemy, GraphQL, Elasticsearch, Docker
- the ability to navigate ambiguity of building something first-of-its-kind
- multiple years of experience building and scaling systems to production-level workloads
- sound technical judgment that considers quality, performance, and product stage
- experience developing software in a startup environment with autonomy and learning focus
- experience interface with bioengineering teams to identify improvements (implied)
- on-call rotation experience (implied)
- preferably experience developing computer-aided design software and/or scientific software applications (desirable)
- Design, build, and maintain software tools used by bioengineers to advance design and manufacture of biologics and gene therapies
- Directly shape software architecture and be involved in long-term product direction
- Work with a modern backend stack (Python 3, Strawberry, SQLAlchemy)
- Develop data models and schemas for complex domain of biology
- Be part of an on-call rotation to support the software you've helped develop
- Interface directly with members of the synthetic biology team to identify and prioritize potential improvements to software systems
- Contribute to Asimov’s technology platform, direction, and culture
- Experience developing computer-aided design software and/or scientific software applications is desired, though not required
What Asimov does: It provides an integrated synthetic biology platform for biopharma, combining cloud-based software for designing, simulating, and optimizing genetic systems with engineered GMP host cells used for therapeutic production. How its products work: The software lets users design and run simulations of genetic circuits and optimize production processes, while engineered cell lines are used to express proteins or produce viral vectors; services include process development and stability studies. How it differs from competitors: It bundles an end-to-end suite—genetic design software, in-house cell-line development, and process development—along with a performance guarantee, such as a 4 g/L monoclonal antibody titer promise, reducing client risk. What its goal is: To help biopharma customers achieve high yields and scalable production of biologics, gene therapies, and programmable medicines through a tightly integrated platform.
Company Size
51-200
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- Licensed LV Edge to AGC Biologics in January 2026 for scalable viral production.
- CHO Edge delivers 8-12 g/L titers; AAV Edge hits 6E15 vg/L for therapies.
- Partners with 25+ biopharma firms, expanding via Boulder office for 95 employees.
What critics are saying
- Ginkgo Bioworks undercuts with cheaper biofoundries, eroding titers in 12-24 months.
- Twist Bioscience commoditizes software at $0.09/bp, capturing market in 6-12 months.
- FDA 2025 purity mandate triggers LV Edge recalls due to integration variability in 6-12 months.
What makes Asimov unique
- Asimov integrates mammalian synthetic biology, CAD software, and ML for genetic design.
- LV Edge achieves E9 TU/mL lentiviral titers with stable cell lines, no transfection.
- Acquired MIT Foundry in 2023 to pioneer advanced genetic circuits at Asimov Labs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -5%BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to access Asimov’s cell line technology to minimize cost and manufacturing risk, depending on their needs:The LV Edge Packaging System, launched earlier this year, which enables a single plasmid transfection that achieves E8 TU/mL.The new, fully-stable LV Edge Producer cell line development service, which generates clones that achieve E9 TU/mL with no transient transfection required.The LV Edge Producer System completely eliminates GMP plasmid cost and greatly reduces process complexity and variability by stably integrating all the genes for lentiviral production into the host cell. Current processes for lentiviral production are inherently scale-limited and variable due to the need for multi-plasmid transient transfection. Furthermore, the reliance on GMP plasmids and transfection reagents substantially increases costs and introduces supply chain and product variability risks. The development of a fully stable cell line technology enables scalable, reproducible and low-cost production of lentivirus, which will unlock applications for larger therapeutic indications
The Foundry, formerly of MIT and the Broad Institute, has joined Asimov; its team, leadership, and infrastructure have moved to Asimov's Boston headquarters.headquarters. The group has nucleated Asimov Labs, a new R&D center for advanced genetic design.BOSTON, Aug. 2, 2023 /PRNewswire/ -- Asimov, the synthetic biology company building tools to design living systems, announced today that The Foundry, previously of MIT and the Broad Institute, has joined its ranks. The Foundry was established by Professor Christopher Voigt (MIT) in 2012 as part of DARPA's Living Foundries program to expand the limits of genetic design. During its tenure, the Foundry developed novel engineering techniques and used them to produce thousands of molecules, materials, genetic circuits, and sensors. In its new home at Asimov, the team will continue to pioneer genetic design as Asimov Labs, a center dedicated to developing technologies to open new frontiers for biological engineering.The Foundry, formerly of MIT and the Broad Institute, has joined AsimovAsimov develops cellular, genetic, and computational tools to enable next-generation therapeutics
LatchBio founders: Alfredo Andere, Kenny Workman, and Kyle Giffin. LatchBioMost industries today are experiencing an unprecedented data deluge – and synthetic biology is no exception. Twenty years ago, a typical biological experiment generated 3-5 megabytes of information. Today, a routine synthetic biology workflow produces anywhere from 1,000 to 40,000 terabytes. That is a billion times more data! Such a large number of data points is simply impossible to interpret by human eye. This is why almost every bio lab today has to set up custom bioinformatics pipelines, invest in cloud computing, and master advanced data visualization software – all that just to see the results of their experiments.A San Francisco startup, LatchBio, hopes to make data analysis much easier for biologists with its full-stack biocomputing infrastructure
Image/Anastasiia SlynkoThe companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds.We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private companies around the world and split them into healthcare and industrial biotechnology-focused verticals.Healthcare investmentsThe U.S.’ top private biotech healthcare investment went to Apogee Therapeutics. The Paragon Therapeutics spinout took home $149 million in a Series B round to fund the development of drugs for a range of undisclosed immunological and inflammatory conditions.An honorable mention goes to Alpha9 Theranostics based in the U.S.’s neighbor, Canada. The firm raised $75 million in a bid to develop radiopharmaceutical treatments for cancer.The top European biotech healthcare investment round went to Pulmocide in the U.K. The firm’s $52 million Series C round will be used to finance the development of inhaled drugs treating viral and fungal infections in the respiratory tract.Content continues below Related ContentThe Chinese firm MaxVax topped the healthcare biotech investment list in Asia-Pacific with a $43 million investment in December 2022
“Before COVID, if I said we need to reproduce or scale, people would ask, why?” says Doug Densmore, Co-Founder of Lattice Automation and Asimov. “Now, people get it.” The consequence? An automated revolution in biotechnology, where cheap computing meets mass-reproducible synthetic biology, begetting an industry with the potential to surpass anything that went before it. The opportunity is […]